Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


1Q preview: Bayer, BMS, Celgene, GSK, Merck & Co, Pfizer and Sanofi

This article was originally published in Scrip

Executive Summary

The first batch of big pharma/big biotech 1Q results has now been released, and the second wave is due in the week beginning 27 April. Among those that have reported, Biogen revealed lower than expected sales of its newest multiple sclerosis therapy Tecfidera (dimethyl fumarate), whereas Novartis with its rival oral MS treatment Gilenya (fingolimod) performed somewhat better. It will be interesting to see how the third oral MS treatment, Aubagio (teriflunomide) performs when Sanofi reports its results. Meanwhile, all the financial results play out against the backdrop of the shifting currency rates and the strengthening dollar, which is having a mixed impact on pharma firms, with US firms like Lilly enjoying bolstered underlying earnings thanks to the impact of currency exchange on its costs, even as revenue performance is held back.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts